As increased TNF-α and IL-6 are associated with the pathogenesis of insulin resistance, biologic DMARDs (e.g., TNF inhibitors and tocilizumab) were expected to decrease DM risk by increasing insulin sensitivity [15,19]. This evidence concerns the gene TNF and Insulin resistance.